Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
more »
- Univ. of Glasgow, Scotland (United Kingdom); London School of Hygiene and Tropical Medicine, London (United Kingdom)
- Vir Biotechnology, San Francisco, CA (United States)
- Univ. of Glasgow, Scotland (United Kingdom)
- Humabs Biomed SA, Bellinzona (Switzerland)
- Univ. of Edinburgh, Scotland (United Kingdom)
- Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
- Memorial Sloan Kettering Cancer Center, New York, NY (United States); Weill Cornell Graduate School of Medical Sciences, New York, NY (United States)
- Memorial Sloan Kettering Cancer Center, New York, NY (United States)
- Univ. of Cambridge (United Kingdom)
- Univ. della Svizzera italiana, Lugano (Switzerland); Inst. of Pharmacological Sciences of Southern Switzerland, Lugano (Switzerland); Univ. Hospital, Zurich (Switzerland)
- Maynooth Univ. (Ireland)
- Ente Ospedaliero Cantonale, Lugano (Switzerland); Univ. of New South Wales, Sydney, NSW (Australia)
- Univ. della Svizzera italiana, Bellinzona (Switzerland); Eidgenoessische Technische Hochschule (ETH), Zurich (Switzerland)
- Clinica Luganese Moncucco, Lugano (Switzerland)
- Luigi Sacco Hospital, Milan (Italy)
- Univ. of Liverpool (United Kingdom); Alder Hey Children's Hospital, Liverpool (United Kingdom)
- Imperial College, London (United Kingdom)
- Univ. of Edinburgh, Scotland (United Kingdom); Royal Infirmary, Edinburgh, Scotland (United Kingdom)
- Vir Biotechnology, San Francisco, CA (United States); Washington Univ., St. Louis, MO (United States)
SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S and provide epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K. We demonstrate N439K S protein has enhanced binding affinity to the hACE2 receptor, and N439K viruses have similar in vitro replication fitness and cause infections with similar clinical outcomes as compared to wild type. We show the N439K mutation confers resistance against several neutralizing monoclonal antibodies, including one authorized for emergency use by the US Food and Drug Administration (FDA), and reduces the activity of some polyclonal sera from persons recovered from infection. Immune evasion mutations that maintain virulence and fitness such as N439K can emerge within SARS-CoV-2 S, highlighting the need for ongoing molecular surveillance to guide development and usage of vaccines and therapeutics.
- Research Organization:
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Sponsoring Organization:
- Bill and Melinda Gates Foundation; Liverpool Experimental Cancer Medicine Centre; Medical Research Council (MRC); National Institutes of Health (NIH); USDOE Office of Science (SC); University of Oxford; Wellcome Trust
- Grant/Contract Number:
- AC02-05CH11231
- OSTI ID:
- 1807486
- Journal Information:
- Cell, Journal Name: Cell Journal Issue: 5 Vol. 184; ISSN 0092-8674
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity
Engineered immunogens to elicit antibodies against conserved coronavirus epitopes
Journal Article
·
Tue Sep 15 20:00:00 EDT 2020
· Cell
·
OSTI ID:1846169
A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity
Journal Article
·
Fri May 26 00:00:00 EDT 2006
· Biochemical and Biophysical Research Communications
·
OSTI ID:20798964
Engineered immunogens to elicit antibodies against conserved coronavirus epitopes
Journal Article
·
Wed Nov 29 19:00:00 EST 2023
· Nature Communications
·
OSTI ID:2470241